Ligand Pharmaceuticals Inc (LGND) 64.13 $LGND
Ligand Pharmaceuticals Shares Down 9.4% Since SmarTrend's Sell Call (LGND)
Comtex SmarTrend(R) - Mon Apr 14, 9:29AM CDT
SmarTrend identified a Downtrend for Ligand Pharmaceuticals (NASDAQ:LGND) on March 26th, 2014 at $69.34. In approximately 3 weeks, Ligand Pharmaceuticals has returned 9.39% as of today's recent price of $62.83.
Brinson Patrick Re-launches Research Department
PR Newswire - Thu Apr 10, 7:21AM CDT
Brinson Patrick Securities Corporation ("Brinson Patrick"
announced today that the firm has re-launched its equity research department with the recent initiation of coverage on several life sciences companies. The research effort is being spearheaded by Christopher James, M.D., Managing Director and Senior Equity Research Analyst.
Healthcare Companies Announce Awards, Partnerships, Milestone Payments, and Conference Schedules - Analyst Notes on Inovio, LifePoint, Mallinckrodt, Ligand, and Theravance
PR Newswire - Wed Apr 02, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Inovio Pharmaceuticals, Inc. (NYSEMKT: INO), LifePoint Hospitals Inc. (NASDAQ: LPNT), Mallinckrodt plc (NYSE: MNK), Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), and Theravance Inc. (NASDAQ: THRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Insider Trading Alert - VLO, LGND And DAR Traded By Insiders
at The Street - Fri Mar 21, 9:30AM CDT
Stocks with insider trader activity include VLO, LGND and DAR
Milestone Payment for Ligand Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 18, 4:30PM CDT
Ligand Pharma receives milestone payment from Merck.
Ligand Pharmaceuticals triggers USD1m milestone payment upon US FDA's approval of Merck's NOXAFIL Injection
M2 - Tue Mar 18, 5:57AM CDT
Biopharmaceutical company Ligand Pharmaceuticals (NasdaqGM:LGND) said on Monday that it expects a USD1m milestone payment following the US Food and Drug Administration's (FDA) approval of Merck's NOXAFIL (posaconazole) injection (18 mg/ml).
Ligand Earns $1 Million Milestone Payment Triggered by FDA Approval of Merck's NOXAFIL(R) (posaconazole) Injection for Intravenous Use, a New Captisol-enabled Formulation
Business Wire - Mon Mar 17, 7:15AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that it has earned a $1 million milestone payment as a result of the recent U.S. Food and Drug Administration (FDA) approval of Merck's NOXAFIL(R) (posaconazole) injection (18 mg/mL). This is a new Captisol(R)-enabled formulation of NOXAFIL for intravenous (IV) use. Ligand will sell Captisol to Merck for this product under a commercial supply agreement.
Bright Outlook at Ligand - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 10:30AM CDT
Ligand provided a rosy outlook at the 2014 Roth Healthcare conference.
Ligand Announces Highlights from Presentation at the 26th Annual Roth Capital Conference
Business Wire - Tue Mar 11, 3:15PM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) presented today at the Roth Capital Conference in Dana Point, California, where it reviewed its business and financial highlights, its unique R&D model and selected un-partnered programs, and provided partnering case studies.
Ligand Pharmaceuticals' NDA for carbamazepine IV accepted for review by US FDA
M2 - Tue Mar 11, 7:19AM CDT
US-based biopharmaceutical company Ligand Pharmaceuticals (NasdaqGM:LGND) said on Monday that the US Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for its investigational intravenous formulation of the anti-epileptic drug, carbamazepine.
Commit To Buy Ligand Pharmaceuticals At $65, Earn 22.6% Annualized Using Options
at The Street - Mon Mar 10, 10:45AM CDT
Investors considering a purchase of Ligand Pharmaceuticals Inc stock, but tentative about paying the going market price of $69.92/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting...
Captisol(R) Licensee Lundbeck Announces FDA Acceptance of NDA Submission for Carbamazepine IV
Business Wire - Mon Mar 10, 9:12AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) Captisol(R) licensee Lundbeck LLC today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for its investigational therapy intravenous carbamazepine, an intravenous formulation of the anti-epileptic drug carbamazepine. An action letter is anticipated before the end of 2014. Carbella(TM) (carbamazepine) Injection is the proposed U.S. trade name. With acceptance of the NDA filing, Ligand earns a $200,000 milestone payment.
Appointments, Earnings Results, Drug Applications, Conferences, and Approvals - Analyst Noteson Boston Scientific, Covidien, St. Jude Medical, Synageva BioPharma, and Ligand Pharmaceuticals
PR Newswire - Wed Mar 05, 3:00PM CST
Editor Note: For more information about this release, please scroll to bottom.
Glaxo/Ligand Look to Expand Promacta Label - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 5:15PM CST
Supplemental New Drug Application (sNDA) for Promacta to the FDA
Ligand Partner GlaxoSmithKline Submits U.S. Regulatory Application for Promacta(R) (eltrombopag) for Severe Aplastic Anaemia
Business Wire - Fri Feb 28, 8:57AM CST
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner GlaxoSmithKline plc (LSE:GSK) announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Promacta(R) (eltrombopag) for the treatment of cytopenias (a reduction in blood cells) in patients with severe aplastic anaemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST).
Ligand to Present at the 26th Annual Roth Conference on March 11
Business Wire - Wed Feb 26, 8:30AM CST
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that John Higgins, President and Chief Executive Officer and Matt Foehr, Chief Operating Officer and Executive Vice President of Ligand, will present at the 26th Annual Roth Conference on Tuesday, March 11, 2014 at 1:30 p.m. Pacific (4:30 p.m. Eastern Time). The conference takes place at The Ritz-Carlton in Dana Point, California.
Insider Trading Alert - LCI, POWI And LGND Traded By Insiders
at The Street - Fri Feb 21, 10:30AM CST
Stocks with insider trader activity include LCI, POWI and LGND
2 Health Care Partnerships Go Head-To-Head
Peter Stephens, The Motley Fool - Motley Fool - Fri Feb 14, 1:30PM CST
The health care space is full of collaborative arrangements, with many pharmaceutical companies in particular forming partnerships with peers to share the development costs (and risk) involved in developing new drugs and treatments. However,...
Research and Markets: US Hospital Hematology and Flow Cytometry Market 2014
Business Wire - Thu Feb 13, 5:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/kjkv69/us_hospital) has announced the addition of the "US Hospital Hematology and Flow Cytometry Market 2014" report to their offering.
Ligand Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 4.27%
Comtex SmarTrend(R) - Wed Feb 12, 5:54PM CST
Ligand Pharmaceuticals (NASDAQ:LGND) traded in a range yesterday that spanned from a low of $70.00 to a high of $76.77. Yesterday, the shares gained 4.3%, which took the trading range above the 3-day high of $71.92 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Ligand Pharmaceuticals Shares Down 9.4% Since SmarTrend's Sell Call (LGND)
Comtex SmarTrend(R) - Mon Apr 14, 9:29AM CDT
SmarTrend identified a Downtrend for Ligand Pharmaceuticals (NASDAQ:LGND) on March 26th, 2014 at $69.34. In approximately 3 weeks, Ligand Pharmaceuticals has returned 9.39% as of today's recent price of $62.83.
Brinson Patrick Re-launches Research Department
PR Newswire - Thu Apr 10, 7:21AM CDT
Brinson Patrick Securities Corporation ("Brinson Patrick"
announced today that the firm has re-launched its equity research department with the recent initiation of coverage on several life sciences companies. The research effort is being spearheaded by Christopher James, M.D., Managing Director and Senior Equity Research Analyst. Healthcare Companies Announce Awards, Partnerships, Milestone Payments, and Conference Schedules - Analyst Notes on Inovio, LifePoint, Mallinckrodt, Ligand, and Theravance
PR Newswire - Wed Apr 02, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Inovio Pharmaceuticals, Inc. (NYSEMKT: INO), LifePoint Hospitals Inc. (NASDAQ: LPNT), Mallinckrodt plc (NYSE: MNK), Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), and Theravance Inc. (NASDAQ: THRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Insider Trading Alert - VLO, LGND And DAR Traded By Insiders
at The Street - Fri Mar 21, 9:30AM CDT
Stocks with insider trader activity include VLO, LGND and DAR
Milestone Payment for Ligand Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 18, 4:30PM CDT
Ligand Pharma receives milestone payment from Merck.
Ligand Pharmaceuticals triggers USD1m milestone payment upon US FDA's approval of Merck's NOXAFIL Injection
M2 - Tue Mar 18, 5:57AM CDT
Biopharmaceutical company Ligand Pharmaceuticals (NasdaqGM:LGND) said on Monday that it expects a USD1m milestone payment following the US Food and Drug Administration's (FDA) approval of Merck's NOXAFIL (posaconazole) injection (18 mg/ml).
Ligand Earns $1 Million Milestone Payment Triggered by FDA Approval of Merck's NOXAFIL(R) (posaconazole) Injection for Intravenous Use, a New Captisol-enabled Formulation
Business Wire - Mon Mar 17, 7:15AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that it has earned a $1 million milestone payment as a result of the recent U.S. Food and Drug Administration (FDA) approval of Merck's NOXAFIL(R) (posaconazole) injection (18 mg/mL). This is a new Captisol(R)-enabled formulation of NOXAFIL for intravenous (IV) use. Ligand will sell Captisol to Merck for this product under a commercial supply agreement.
Bright Outlook at Ligand - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 10:30AM CDT
Ligand provided a rosy outlook at the 2014 Roth Healthcare conference.
Ligand Announces Highlights from Presentation at the 26th Annual Roth Capital Conference
Business Wire - Tue Mar 11, 3:15PM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) presented today at the Roth Capital Conference in Dana Point, California, where it reviewed its business and financial highlights, its unique R&D model and selected un-partnered programs, and provided partnering case studies.
Ligand Pharmaceuticals' NDA for carbamazepine IV accepted for review by US FDA
M2 - Tue Mar 11, 7:19AM CDT
US-based biopharmaceutical company Ligand Pharmaceuticals (NasdaqGM:LGND) said on Monday that the US Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for its investigational intravenous formulation of the anti-epileptic drug, carbamazepine.
Commit To Buy Ligand Pharmaceuticals At $65, Earn 22.6% Annualized Using Options
at The Street - Mon Mar 10, 10:45AM CDT
Investors considering a purchase of Ligand Pharmaceuticals Inc stock, but tentative about paying the going market price of $69.92/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting...
Captisol(R) Licensee Lundbeck Announces FDA Acceptance of NDA Submission for Carbamazepine IV
Business Wire - Mon Mar 10, 9:12AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) Captisol(R) licensee Lundbeck LLC today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for its investigational therapy intravenous carbamazepine, an intravenous formulation of the anti-epileptic drug carbamazepine. An action letter is anticipated before the end of 2014. Carbella(TM) (carbamazepine) Injection is the proposed U.S. trade name. With acceptance of the NDA filing, Ligand earns a $200,000 milestone payment.
Appointments, Earnings Results, Drug Applications, Conferences, and Approvals - Analyst Noteson Boston Scientific, Covidien, St. Jude Medical, Synageva BioPharma, and Ligand Pharmaceuticals
PR Newswire - Wed Mar 05, 3:00PM CST
Editor Note: For more information about this release, please scroll to bottom.
Glaxo/Ligand Look to Expand Promacta Label - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 5:15PM CST
Supplemental New Drug Application (sNDA) for Promacta to the FDA
Ligand Partner GlaxoSmithKline Submits U.S. Regulatory Application for Promacta(R) (eltrombopag) for Severe Aplastic Anaemia
Business Wire - Fri Feb 28, 8:57AM CST
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner GlaxoSmithKline plc (LSE:GSK) announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Promacta(R) (eltrombopag) for the treatment of cytopenias (a reduction in blood cells) in patients with severe aplastic anaemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST).
Ligand to Present at the 26th Annual Roth Conference on March 11
Business Wire - Wed Feb 26, 8:30AM CST
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that John Higgins, President and Chief Executive Officer and Matt Foehr, Chief Operating Officer and Executive Vice President of Ligand, will present at the 26th Annual Roth Conference on Tuesday, March 11, 2014 at 1:30 p.m. Pacific (4:30 p.m. Eastern Time). The conference takes place at The Ritz-Carlton in Dana Point, California.
Insider Trading Alert - LCI, POWI And LGND Traded By Insiders
at The Street - Fri Feb 21, 10:30AM CST
Stocks with insider trader activity include LCI, POWI and LGND
2 Health Care Partnerships Go Head-To-Head
Peter Stephens, The Motley Fool - Motley Fool - Fri Feb 14, 1:30PM CST
The health care space is full of collaborative arrangements, with many pharmaceutical companies in particular forming partnerships with peers to share the development costs (and risk) involved in developing new drugs and treatments. However,...
Research and Markets: US Hospital Hematology and Flow Cytometry Market 2014
Business Wire - Thu Feb 13, 5:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/kjkv69/us_hospital) has announced the addition of the "US Hospital Hematology and Flow Cytometry Market 2014" report to their offering.
Ligand Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 4.27%
Comtex SmarTrend(R) - Wed Feb 12, 5:54PM CST
Ligand Pharmaceuticals (NASDAQ:LGND) traded in a range yesterday that spanned from a low of $70.00 to a high of $76.77. Yesterday, the shares gained 4.3%, which took the trading range above the 3-day high of $71.92 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
